ARWR Arrowhead Pharmaceuticals, Inc.

43.94USD+0.68%Mkt Cap: 6.17B USDP/E: —

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasir…

Institutional holders20 on file

Key Statistics

Company
Market Cap6.17B USD
Enterprise Value6.39B USD
Revenue (TTM)450.82M USD
Gross Profit449.02M USD
Net Income (TTM)-724.21M USD
Revenue/Share3.18 USD
Last Price43.94 USD
Fiscal Year EndSep 2026
MR QuarterSep 2026
Employees1.1K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-10.83
PEG—
EV/EBITDA-9.39
EV/Revenue14.17
P/S13.69
P/B122.61
EPS (TTM)-5.11 USD
EPS (Forward)-4.03 USD
52W Range
37.0612% of range95.49
52W High95.49 USD
52W Low37.06 USD
Profitability
Gross Margin99.60%
Oper. Margin-156.86%
EBITDA Margin-150.96%
Profit Margin-160.64%
ROE-1439.40%
ROA-41.66%
ROIC—
ROCE-49.56%
Growth
Revenue Growth-85.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-271.95M USD
CapEx (TTM)11.99M USD
FCF Margin-130.21%
FCF Yield-9.51%
Net Debt218.59M USD
Net Debt/EBITDA-0.32
Net Debt/FCF—
Balance Sheet
Debt/Equity19.88
Current Ratio4.14
Quick Ratio3.92
Book Value/Sh0.36 USD
Cash/Share8.41 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateNov 17, 2011
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)105.86 USD
Upside (mean)+140.9%
Target Range73.00 USD – 126.00 USD
73.00+140.9% to mean126.00
# Analysts14
Ownership
Shares Out.141.37M
Float122.91M
Insiders3.65%
Institutions86.88%
Short Interest
Short Ratio6.7d
Short % Float11.40%
Short % Out.8.20%
Shares Short11.58M
Short (prev mo.)10.76M
Technical
SMA 5060.85 (-27.8%)
SMA 20070.66 (-37.8%)
Beta1.37
S&P 52W Chg12.00%
Avg Vol (30d)2.11M
Avg Vol (10d)2.96M
Technical Indicators
RSI (14)23.3
MACD-5.1820
MACD Signal-4.3048
MACD Hist.-0.8773
BB Upper67.42 USD
BB Middle53.47 USD
BB Lower39.53 USD
BB Width52.14%
ATR (14)2.916 USD
Vol Ratio (20d)1.22x

About Arrowhead Pharmaceuticals (NASDAQ: ARWR)

›

Arrowhead Pharmaceuticals (NASDAQ: ARWR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 1,062 employees.

The shares were at 43.94 USD on 20 November 2026, up 10.2% over 52 weeks. Its 52-week range is 37.06 USD to 95.49 USD: the price is 54.0% below the high and 18.6% above the low.

Its market capitalisation is 6.17B USD.

Arrowhead Pharmaceuticals reports an operating margin of -156.9% and revenue down 85.3% year over year.

Its debt exceeds its cash by 218.59M USD, a debt-to-equity ratio of 19.88. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 14 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 105.86 USD is 140.9% above the current price. The next earnings report is expected on 24 November 2026.